+44 (0) 1223 696000
Content of this page is provided and copyrighted by the exhibitor. Click follow exhibitor to be notified of new content.
Copyright © 2018 Abcam plc.
At Abcam we make sure that neuroscientists have the tools they need to conduct the best research. In addition to our in-house R&D capabilities, we work with collaborators like the Michael J Fox Foundation (MJFF), academic experts, and some of the best in the industry. As a result, we give you access to over 17,000 neuroscience reagents from a catalog of over 130,000 life science reagents and tools.
You can get to the root of Parkinson's disease with rabbit monoclonal antibodies developed with MJFF against key targets like leucine-rich repeat kinase 2 (LRRK2), DJ-1, RAB8A and RAB10, and a conformation-specific alpha-synuclein filament. You can also investigate proteins in specific states in your Alzheimer’s disease research with our rabbit monoclonal antibodies against amyloid-beta 1–42 fibrils, developed in collaboration with Professor Charles Glabe (UC Irvine), to distinguish conformational variation in amyloid structures. Whether you need primary antibodies against neuronal and glial markers, calcium signaling resources, ELISA kits against neuronal targets, multiplex immunoassay options, proteins and lysates, or even protocols, we can help you get the most from your neuroscience research.
The Virtual Exhibit Hall is paid advertising. FBRI has not been involved in the preparation, adoption or editing of Third Party Content. While FBRI makes every attempt to provide accurate and timely information to serve the needs of users, neither FBRI nor the Third Party Content Providers guarantee its accuracy, timeliness, completeness or usefulness, and are not responsible or liable for any such content, including any advertising, products, or other materials on or available from third party sites. FBRI and the Third Party Content Providers specifically disclaim any responsibility for Content available on the Site. The use of the Site and the Content, including Third Party Content, is at your own risk.